A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX

被引：1

作者：

Su, M-H. ^{[1
]}

机构：

[1] NDMC Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.118

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

82P

引用

页码：S1465 / S1465

页数：1

共 50 条

[31] A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti-super-enhancer triptolide analogue with nab-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.
Park, Joon Oh
Hong, Jung Yong
Kim, Seung Tae
Park, Young Suk
Saluja, Ashok
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS769 - TPS769
[32] Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Yalcin, Suayib
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye Yildirim
Isikdogan, Abdurrahman
Ozkan, Metin
Demirag, Guzin Gonullu
Coskun, Hasan Senol
Karabulut, Bulent
Evrensel, Turkkan
Ustaoglu, Mehmet Ali
Ozdemir, Feyyaz
Turna, Hande
Yavuzsen, Tugba
Aykan, Faruk
Sevinc, Alper
Akbulut, Hakan
Yuce, Deniz
Hayran, Mutlu
Kilickap, Saadettin
BMC CANCER, 2020, 20 (01)
[33] KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.
Jo, Jung Hyun
Kim, Yong-Tae
Choi, Ho Soon
Kim, Ho Gak
Lee, Hong Sik
Choi, Young Woo
Kim, Dong Uk
Lee, Kwang Hyuck
Kim, Eui Joo
Han, Jeong Ho
Lee, Seung Ok
Park, Chang-Hwan
Choi, Eun Kwang
Lee, Kyong Joo
Cho, Jae Yong
Lee, Woo Jin
Song, Si Young
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial
Ohba, A.
Ozaka, M.
Ogawa, G.
Okusaka, T.
Kobayashi, S.
Yamashita, T.
Ikeda, M.
Yasuda, I.
Sugimori, K.
Sasahira, N.
Ikezawa, K.
Miki, I.
Okano, N.
Mizuno, N.
Furukawa, M.
Shirakawa, H.
Sano, Y.
Katayama, H.
Furuse, J.
Ueno, M.
ANNALS OF ONCOLOGY, 2023, 34 : S894 - S894
[35] Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy
Hohmann, Nicolas
Sprick, Martin Ronald
Ahmed, Azaz
Burhenne, Juergen
Kirchner, Marietta
Le Cornet, Lucian
Kratzmann, Markus
Hajda, Jacek
Stenzinger, Albrecht
Steindorf, Karen
Delorme, Stefan
Schlemmer, Heinz-Peter
Riethdorf, Sabine
van Schaik, Ron
Pantel, Klaus
Siveke, Jens
Seufferlein, Thomas
Jaeger, Dirk
Haefeli, Walter E.
Trumpp, Andreas
Springfeld, Christoph
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (12): : 2483 - 2493
[36] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
Choi, Jin Ho
Lee, Hee Seung
Huh, Gunn
Lee, Sang Hyub
Paik, Woo Hyun
Ryu, Ji Kon
Kim, Yong-Tae
Bang, Seungmin
Lee, Eaum Seok
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
[37] A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naive advanced or metastatic biliary tract cancer: first safety and efficacy data
Moehler, M.
Kanzler, S.
Schimanski, C. C.
Woerns, M. A.
Denzer, U.
Kolligs, F.
Ebert, M.
Distelrath, A.
Zeuzem, S.
Lammert, F.
Geissler, M.
Lohse, A.
Dollinger, M.
Lindig, U.
Duerr, M.
Lubomierski, N.
Kabisch, M.
Schadmand-Fischer, S.
Galle, P. R.
ONKOLOGIE, 2011, 34 : 217 - 217
[38] PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
Abou-Alfa, Ghassan K.
Borbath, Ivan
Goyal, Lipika
Lamarca, Angela
Macarulla, Teresa
Oh, Do-Youn
Roychowdhury, Sameek
Sadeghi, Saeed
Shroff, Rachna T.
Li, Ai
Soto, Jose
Avogadri, Francesca
Dambkowski, Carl L.
Javle, Milind M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Zhu, Xiaofei
Cao, Yangsen
Liu, Wenyu
Ju, Xiaoping
Zhao, Xianzhi
Jiang, Lingong
Ye, Yusheng
Jin, Gang
Zhang, Huojun
LANCET ONCOLOGY, 2022, 23 (03): : E105 - E115
[40] Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone:: A randomized multicenter phase III clinical trial -: SAKK 44/00-CECOG/PAN.1.3.001
Bernhard, Juerg
Dietrich, Daniel
Scheithauer, Werner
Gerber, Daniela
Bodoky, Gyo Rgy
Ruhstaller, Thomas
Glimelius, Bengt
Bajetta, Emilio
Schueller, Johannes
Saletti, Piercarlo
Bauer, Jean
Figer, Arie
Pestalozzi, Bernhard C.
Hne, Claus-Henning Ko
Mingrone, Walter
Stemmer, Salomon M.
Tamas, Karin
Kornek, Gabriela V.
Koeberle, Dieter
Herrmann, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3695 - 3701

← 1 2 3 4 5 →